Peripheral arterial disease and hypertension Article

Full Text via DOI: 10.1097/HCO.0000000000000983 Web of Science: 000837761700004

Cited authors

  • Gupta A, Patel RAG


  • Purpose of review Hypertension (HTN) is a well known risk factor for atherosclerosis and peripheral arterial disease (PAD). PAD affects more than 250 million people globally and is associated with worse clinical outcomes. Although multiple studies have been performed to evaluate treatment of HTN in patients with PAD, blood pressure management in this high-risk cohort remains poor. Recent findings There has been conflicting evidence regarding blood pressure goals in PAD with some recent studies showing adverse outcomes with low blood pressure in this patient population. Current guidelines, however, continue to recommend treatment goals in PAD patients similar to patients without PAD. To date, no single antihypertensive drug class has shown a clear benefit in PAD population over other antihypertensive drug classes. Prospective randomized trials enrolling PAD patients are required that can shed light on optimum blood pressure target and also distinguish between different antihypertensive drugs in terms of reducing adverse outcomes.

Publication date

  • 2022

Published in

International Standard Serial Number (ISSN)

  • 0268-4705

Number of pages

  • 10

Start page

  • 403

End page

  • 412


  • 37


  • 5